Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia

Matthew Wilson, J. L. Hungerford, S. M. George, S. A. Madreperla

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

PURPOSE: To evaluate the efficacy of topical mitomycin C in treating conjunctival and corneal epithelial dysplasia and neoplasia. METHODS: Seven eyes of seven patients with conjunctival and corneal epithelial dysplasia and neoplasia were treated with one drop of topical mitomycin C 0.04% four times a day for 7 days in alternate weeks. The patients' charts were reviewed retrospectively. Patients with either multiple recurrences or extensive ocular surface involvement were treated. In all eyes, the diagnosis of epithelial dysplasia or neoplasia was confirmed by histopathology before the onset of therapy. Patients were examined at least every 14 days during treatment and examined at intervals after completion of treatment. RESULTS: With topical mitomycin C, six eyes of seven patients had complete clinical regression of their conjunctival and corneal epithelial dysplasia and neoplasia. One eye of one patient had partial clinical regression of conjunctival and corneal epithelial dysplasia. Follow-up after completion of topical mitomycin C therapy and excision of residual disease ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without clinical sign of recurrence. Topical mitomycin C therapy was associated with transitory ocular discomfort, conjunctival injection, tearing, photophobia, and punctate epithelial keratopathy. CONCLUSION: In this small series of eyes, topical mitomycin C was effective as a treatment for conjunctival and corneal epithelial dysplasia and neoplasia.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalAmerican Journal of Ophthalmology
Volume124
Issue number3
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Mitomycin
Neoplasms
Therapeutics
Recurrence
Photophobia
Injections

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. / Wilson, Matthew; Hungerford, J. L.; George, S. M.; Madreperla, S. A.

In: American Journal of Ophthalmology, Vol. 124, No. 3, 01.01.1997, p. 303-311.

Research output: Contribution to journalArticle

Wilson, Matthew ; Hungerford, J. L. ; George, S. M. ; Madreperla, S. A. / Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. In: American Journal of Ophthalmology. 1997 ; Vol. 124, No. 3. pp. 303-311.
@article{665d36fae2bc4765a6007e6fc6545a34,
title = "Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia",
abstract = "PURPOSE: To evaluate the efficacy of topical mitomycin C in treating conjunctival and corneal epithelial dysplasia and neoplasia. METHODS: Seven eyes of seven patients with conjunctival and corneal epithelial dysplasia and neoplasia were treated with one drop of topical mitomycin C 0.04{\%} four times a day for 7 days in alternate weeks. The patients' charts were reviewed retrospectively. Patients with either multiple recurrences or extensive ocular surface involvement were treated. In all eyes, the diagnosis of epithelial dysplasia or neoplasia was confirmed by histopathology before the onset of therapy. Patients were examined at least every 14 days during treatment and examined at intervals after completion of treatment. RESULTS: With topical mitomycin C, six eyes of seven patients had complete clinical regression of their conjunctival and corneal epithelial dysplasia and neoplasia. One eye of one patient had partial clinical regression of conjunctival and corneal epithelial dysplasia. Follow-up after completion of topical mitomycin C therapy and excision of residual disease ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without clinical sign of recurrence. Topical mitomycin C therapy was associated with transitory ocular discomfort, conjunctival injection, tearing, photophobia, and punctate epithelial keratopathy. CONCLUSION: In this small series of eyes, topical mitomycin C was effective as a treatment for conjunctival and corneal epithelial dysplasia and neoplasia.",
author = "Matthew Wilson and Hungerford, {J. L.} and George, {S. M.} and Madreperla, {S. A.}",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0002-9394(14)70822-0",
language = "English (US)",
volume = "124",
pages = "303--311",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

TY - JOUR

T1 - Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia

AU - Wilson, Matthew

AU - Hungerford, J. L.

AU - George, S. M.

AU - Madreperla, S. A.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - PURPOSE: To evaluate the efficacy of topical mitomycin C in treating conjunctival and corneal epithelial dysplasia and neoplasia. METHODS: Seven eyes of seven patients with conjunctival and corneal epithelial dysplasia and neoplasia were treated with one drop of topical mitomycin C 0.04% four times a day for 7 days in alternate weeks. The patients' charts were reviewed retrospectively. Patients with either multiple recurrences or extensive ocular surface involvement were treated. In all eyes, the diagnosis of epithelial dysplasia or neoplasia was confirmed by histopathology before the onset of therapy. Patients were examined at least every 14 days during treatment and examined at intervals after completion of treatment. RESULTS: With topical mitomycin C, six eyes of seven patients had complete clinical regression of their conjunctival and corneal epithelial dysplasia and neoplasia. One eye of one patient had partial clinical regression of conjunctival and corneal epithelial dysplasia. Follow-up after completion of topical mitomycin C therapy and excision of residual disease ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without clinical sign of recurrence. Topical mitomycin C therapy was associated with transitory ocular discomfort, conjunctival injection, tearing, photophobia, and punctate epithelial keratopathy. CONCLUSION: In this small series of eyes, topical mitomycin C was effective as a treatment for conjunctival and corneal epithelial dysplasia and neoplasia.

AB - PURPOSE: To evaluate the efficacy of topical mitomycin C in treating conjunctival and corneal epithelial dysplasia and neoplasia. METHODS: Seven eyes of seven patients with conjunctival and corneal epithelial dysplasia and neoplasia were treated with one drop of topical mitomycin C 0.04% four times a day for 7 days in alternate weeks. The patients' charts were reviewed retrospectively. Patients with either multiple recurrences or extensive ocular surface involvement were treated. In all eyes, the diagnosis of epithelial dysplasia or neoplasia was confirmed by histopathology before the onset of therapy. Patients were examined at least every 14 days during treatment and examined at intervals after completion of treatment. RESULTS: With topical mitomycin C, six eyes of seven patients had complete clinical regression of their conjunctival and corneal epithelial dysplasia and neoplasia. One eye of one patient had partial clinical regression of conjunctival and corneal epithelial dysplasia. Follow-up after completion of topical mitomycin C therapy and excision of residual disease ranged from 2 to 16 months (mean, 9 months; SD, 4.3 months) and was without clinical sign of recurrence. Topical mitomycin C therapy was associated with transitory ocular discomfort, conjunctival injection, tearing, photophobia, and punctate epithelial keratopathy. CONCLUSION: In this small series of eyes, topical mitomycin C was effective as a treatment for conjunctival and corneal epithelial dysplasia and neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=0030851872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851872&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(14)70822-0

DO - 10.1016/S0002-9394(14)70822-0

M3 - Article

VL - 124

SP - 303

EP - 311

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -